266 related articles for article (PubMed ID: 33116950)
1.
El Darsa H; El Sayed R; Abdel-Rahman O
J Exp Pharmacol; 2020; 12():349-361. PubMed ID: 33116950
[TBL] [Abstract][Full Text] [Related]
2. SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer.
De Marco K; Lepore Signorile M; Di Nicola E; Sanese P; Fasano C; Forte G; Disciglio V; Pantaleo A; Varchi G; Del Rio A; Grossi V; Simone C
Cells; 2023 Oct; 12(20):. PubMed ID: 37887325
[TBL] [Abstract][Full Text] [Related]
3. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
4. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
5. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
6. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
7. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
8. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
9. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
10. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
11. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
12. MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
Farrell PJ; Matuszkiewicz J; Balakrishna D; Pandya S; Hixon MS; Kamran R; Chu S; Lawson JD; Okada K; Hori A; Mizutani A; Iwata H; de Jong R; Hibner B; Vincent P
Mol Cancer Ther; 2017 Jul; 16(7):1269-1278. PubMed ID: 28341789
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
14. Personalized therapeutic strategies in HER2-driven gastric cancer.
Ughetto S; Migliore C; Pietrantonio F; Apicella M; Petrelli A; D'Errico L; Durando S; Moya-Rull D; Bellomo SE; Rizzolio S; Capelôa T; Ribisi S; Degiuli M; Reddavid R; Rapa I; Fumagalli U; De Pascale S; Ribero D; Baronchelli C; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Manenti S; Bencivenga M; Sacco M; Castelli C; Siena S; Sartore-Bianchi A; Tosi F; Morano F; Raimondi A; Prisciandaro M; Gloghini A; Marsoni S; Sottile A; Sarotto I; Sapino A; Marchiò C; Cassoni P; Guarrera S; Corso S; Giordano S
Gastric Cancer; 2021 Jul; 24(4):897-912. PubMed ID: 33755862
[TBL] [Abstract][Full Text] [Related]
15. Current advances of targeting HGF/c-Met pathway in gastric cancer.
Anestis A; Zoi I; Karamouzis MV
Ann Transl Med; 2018 Jun; 6(12):247. PubMed ID: 30069449
[TBL] [Abstract][Full Text] [Related]
16. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of MET in gastric cancer.
Inokuchi M; Otsuki S; Fujimori Y; Sato Y; Nakagawa M; Kojima K
World J Gastrointest Oncol; 2015 Nov; 7(11):317-27. PubMed ID: 26600931
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
19. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
[TBL] [Abstract][Full Text] [Related]
20. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]